Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815975 | 1.00 | MEN1 (0.53) | MEN1KMT2AALDH1A1MAPK1ALOX15 | |
| SCHEMBL7434688 | 0.91 | GAA (0.62) | MEN1KMT2AALDH1A1MAPK1ALOX15 | |
| SCHEMBL6687492 | 0.83 | MEN1 (0.62) | MEN1KMT2AALDH1A1MAPK1ALOX15 | |
| SCHEMBL7435769 | 0.83 | MAPT (0.60) | MEN1KMT2AALDH1A1MAPK1PKM | |
| Hydrochloric Acid SCHEMBL7438235 | 0.82 | MCHR1 (0.52) | MEN1KMT2AALDH1A1HSD17B10MAPT | |
| SCHEMBL7436155 | 0.81 | MAPT (0.42) | MEN1KMT2AALDH1A1MAPK1ALOX15 | |
| SCHEMBL7444066 | 0.81 | MAPT (0.42) | MEN1KMT2AALDH1A1MAPK1ALOX15 | |
| SCHEMBL14742925 | 0.81 | KMT2A (0.62) | MEN1KMT2AALDH1A1MAPK1ALOX15 | |
| SCHEMBL7436562 | 0.81 | PTGS2 (0.45) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL7433535 | 0.79 | MAPT (0.57) | MEN1KMT2AALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | GLAS USA LLC | 2021-02-04 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| WO-2019246317-A9 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | PROGENITY, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2019147824-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PROGENITY, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019036382-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | PROGENITY INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-2193808-A1 | Synergistic combination | Nycomed GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | MEN1 951/4885KMT2A 2541/4885ALDH1A1 2119/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | MEN1 1193/4885KMT2A 2642/4885ALDH1A1 3155/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | MEN1 2567/4885KMT2A 3261/4885ALDH1A1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.